In its October 29 announcement, Hims & Hers introduced plans for a new Peptides+ program combining clinician-guided treatment, pharmacy fulfillment, and access to peptide and related wellness therapies.
Hims & Hers Outlines Peptides+ Treatment and Telehealth Care Model
On October 29, 2026, Hims & Hers co-founder and CEO Andrew Dudum outlined plans to introduce sermorelin, glutathione, NAD+, and other wellness treatments through its Peptides+ program, with BPC-157 and TB-500 planned for a later phase, subject to regulatory conditions. The telehealth company’s announcement details a proposed care model involving clinical evaluation, prescribing by licensed healthcare providers, and pharmacy fulfillment.
Details of Hims & Hers’ Peptides+ Program and Care Model
As detailed in the company’s announcement, the Peptides+ program is currently in its early-access registration phase, with sign-ups available through the Hims and Hers websites. The company has outlined its proposed treatment offerings and clinical delivery arrangements, with no specific launch date announced.
Dudum identified the following planned treatment offerings:
- Initial planned offerings: Sermorelin, glutathione, NAD+, vitamin B12, and L-carnitine.
- Future offerings: BPC-157 and TB-500, subject to regulatory conditions permitting their introduction.
The announcement outlined a proposed clinical delivery model involving:
- Treatment eligibility: For eligible patients, independent licensed healthcare providers would prescribe individualized treatment plans.
- Pharmacy fulfillment: Prescribed treatments supplied through U.S.-licensed pharmacies.
- Ongoing care: Continued clinical support throughout treatment.
The company’s Peptides+ registration pages describe the following sourcing and quality-control procedures:
- Ingredient sourcing: Active ingredients sourced from FDA-registered facilities.
- Product testing: Ready-to-inject vials tested for purity and potency.
- Storage and shipment: Treatments stored, handled, and packaged for shipment under the company’s procedures.
Dudum stated in the October 29 announcement that Hims & Hers had spent years developing infrastructure at its U.S.-based peptide manufacturing facility and working with clinical experts to establish dosing protocols. He also acknowledged that published research remains limited for many of these compounds and that the company plans to rely on provider-supervised use as it develops the program. The company’s Peptides+ registration pages disclose that the featured compounded treatments are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.
Source Attribution
According to an October 29, 2026 announcement by Hims & Hers, the company’s Peptides+ waitlist is open, with plans for clinician-guided treatment, licensed-pharmacy fulfillment, and ongoing clinical support.
DISCOVER YOUR MED SPA’S GROWTH POTENTIAL
How much time and revenue could you unlock by outsourcing your GFEs?
Use our GFE Calculator to find out in under 5 minutes. It’s quick, easy, and tailored to your Med Spa.
Broader Regulatory Context of Peptide-Based Treatments and Telehealth Services
The Hims & Hers announcement referenced the interim peptide enforcement discretion policy released by the U.S. Department of Health and Human Services (HHS) the previous day. The HHS policy covers six peptide bulk drug substances, including BPC-157 and TB-500, under specified conditions for qualifying Section 503A compounders while the Food and Drug Administration (FDA) continues its formal rulemaking process.
The interim policy does not grant FDA approval to the substances in Appendix A. Under federal law, Section 503A establishes conditions for qualifying drug compounding, including patient-specific prescription requirements. The FDA retains federal oversight of drug compounding, while state licensing and professional practice requirements remain applicable.
Prescription-based telehealth services have also expanded into other treatment categories involving FDA-approved medications. In April 2026, Amazon One Medical introduced a GLP-1 Management Program combining clinical evaluation, prescribing, follow-up care, and pharmacy access for weight-management treatment.
Peptide and related wellness treatments are also represented in U.S. Med Spa service listings. A September 2026 Whelth Research analysis of 14,748 U.S. Med Spa websites found that 11.4% listed peptide therapy, 13% NAD+ therapy, and 40.1% medical weight loss. These percentages reflect services identified on practice websites rather than independently verified treatment delivery.
Following the release of HHS’s interim peptide compounding policy, Hims & Hers announced its Peptides+ waitlist, outlining plans for clinician-guided peptide and wellness treatments with licensed-pharmacy fulfillment.
For Med Spa, wellness, and telehealth operators, federal and state requirements for prescribing, pharmacy licensing, compounding, scope of practice, and medical oversight continue to apply based on the treatment and jurisdiction.
Practical Implications for Med Spa, Wellness, and Telehealth Operations
- Assess federal and state regulatory requirements and lawful pathways for peptide-based treatments.
- Monitor FDA peptide rulemaking, HHS policy updates, and applicable state guidance.
- Define provider roles in telehealth evaluations, prescribing, and ongoing patient support.
- Align patient-facing materials with treatment availability, FDA approval status, and product disclosures.
- Track industry treatment expansions and related prescribing and pharmacy fulfillment requirements.
What to Watch Next
As of this reporting, Hims & Hers has opened early-access registration for its Peptides+ program, with BPC-157 and TB-500 planned for a later phase, subject to regulatory conditions. Further developments from HHS and the FDA concerning peptide compounding and the Section 503A Bulks List may clarify the regulatory conditions governing these substances and their availability.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Close Up Image of Vaccination Tubes,” via Vecteezy, available under the Vecteezy Free License.





